Semax

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. It was developed in Russia and has been used clinically since the 1990s for neurological disorders, especially stroke recovery Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Unlike the parent hormone ACTH, Semax lacks corticosteroid activity and instead acts as a neuroprotective agent Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

The compound is most commonly administered intranasally to bypass the blood-brain barrier, with research focusing on its ability to upregulate brain-derived neurotrophic factor (BDNF), reduce neuroinflammation, and support neuronal repair Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. While approved in Russia, Semax remains investigational in most Western countries Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Semax works through multiple pathways that converge on neuroprotection Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. Its primary mechanism involves enhancing BDNF signaling, a key neurotrophin that promotes neuron survival and synaptic plasticity Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain‐derived neurotrophic factor protein in rat basal forebrain. Semax binds specifically in rat basal forebrain membrane preparations and increases BDNF protein after intranasal dosing Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain‐derived neurotrophic factor protein in rat basal forebrain.

A second major target is the μ-opioid receptor (Oprm1), where Semax regulates deubiquitination and downstream cell survival pathways, as shown in spinal cord injury models Semax peptide targets the μ opioid receptor gene <i>Oprm1</i> to promote deubiquitination and functional recovery after spinal cord injury in female mice. This positions Semax within a receptor-to-deubiquitinase signaling cascade rather than a simple trophic peptide class Semax peptide targets the μ opioid receptor gene <i>Oprm1</i> to promote deubiquitination and functional recovery after spinal cord injury in female mice.

Additional actions include:

• Modulation of calcium dynamics in hippocampal neurons, suggesting region-specific network effects The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons
• Anti-inflammatory transcriptomic reprogramming, suppressing genes like Il1b and Il6 while upregulating neurotransmission-related genes Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain following the Early Post-Stroke Period+1
• Copper chelation and redox silencing, which may protect against amyloid-beta toxicity in Alzheimer's models Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing+1
• Activation of PGC-1α, supporting mitochondrial biogenesis and angiogenesis Protective Effects of PGC-1α Activators on Ischemic Stroke in a Rat Model of Photochemically Induced Thrombosis

Stroke and Ischemia Semax shows consistent benefits in animal models of ischemic stroke and is used clinically in Russia for stroke recovery Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. In rat studies, intranasal Semax preserved neuronal PGC-1α expression, reduced infarct volume, and improved functional outcomes Protective Effects of PGC-1α Activators on Ischemic Stroke in a Rat Model of Photochemically Induced Thrombosis. Transcriptomic analyses reveal a shift from inflammatory to reparative gene expression patterns Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain following the Early Post-Stroke Period.

Cognitive Function In Alzheimer's disease models, Semax reduced amyloid plaque burden and improved cognitive performance The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Healthy user reports and practitioner consensus suggest enhanced focus and mental clarity, though controlled human trials are lacking Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Spinal Cord Injury Preclinical studies demonstrate early anti-inflammatory effects, with increased IL-10 and IL-13 within hours of injury, and improved locomotor recovery linked to μ-opioid receptor modulation Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats)+1.

Mood and Stress In chronic stress models, Semax reversed anhedonia, preserved hippocampal BDNF, and normalized stress-induced adrenal changes Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. It also mitigated behavioral changes from early-life SSRI exposure Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.

Semax is primarily used intranasally, with no standard injectable or oral protocols Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. Published regimens range from low-dose nootropic use to higher-dose supervised stroke protocols.

Typical Nootropic Protocol

• Dose: 300-900 mcg/day, divided into 1-3 administrations (morning and early afternoon) Therapeutic peptides in gerontology: mechanisms and applications for healthy aging[community protocol]
• Duration: 10-14 day cycles, followed by 1-2 weeks off [community protocol]
• Practical: 100-300 mcg per spray, depending on solution concentration [community protocol]

Stroke Recovery Protocol (Clinical)

• Dose: 6000 mcg/day intranasally for 10 days, repeated for two courses with a 20-day interval Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
• This high-dose regimen was used in Russian clinical settings and is significantly higher than common nootropic protocols Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Timing and Cycling

• Morning dosing is preferred to avoid sleep disruption [community protocol]
• Short 7-14 day cycles with breaks minimize potential tolerance Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
• Effects on cognition may stabilize within 3-7 days [community protocol]

Semax modulates multiple neurotransmitter systems, creating potential interactions with centrally-acting drugs.

CNS Depressants

Semax affects GABA- and glycine-activated currents and μ-opioid signaling, so caution is advised with alcohol, benzodiazepines, gabapentinoids, and opioids Modulation of GABA- and Glycine-Activated Ionic Currents with Semax in Isolated Cerebral Neurons+1. Sedation or altered analgesic responses may occur.

Stimulants and Antidepressants

Dopaminergic and serotonergic activation could amplify effects of amphetamines, methylphenidate, or SSRIs, increasing risk of overstimulation, anxiety, or serotonin syndrome Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

Copper and Metal Chelators

Semax is a high-affinity Cu(II) binder that can strip copper from amyloid-beta complexes Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing+1. Concurrent use with copper supplements or chelation therapies may alter copper homeostasis.

Peptide Combinations

Semax is often stacked with Selank for a combined cognitive-anxiolytic effect, though overlapping CNS effects require careful dosing Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives[community protocol]. Avoid mixing with other neuroactive peptides until individual responses are established.

Semax is frequently combined with other peptides to target specific outcomes.

Semax + Selank

A popular stack for balanced cognitive enhancement and anxiety reduction. Selank provides anxiolytic effects while Semax supports focus and neuroprotection Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives[community protocol]. Starting one peptide at a time is recommended to assess individual response.

Semax + Melanocortin Peptides

Both Semax and Melanotan II share ACTH-derived structures and antidepressant-like properties Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. Potential synergy in stress modulation, but overlapping effects on appetite, blood pressure, and arousal warrant caution.

Semax + Neurotrophic Peptides

Stacking with neuroprotective or regenerative peptides (e.g., Cerebrolysin) may amplify BDNF-related repair, though human data are sparse Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain‐derived neurotrophic factor protein in rat basal forebrain.

Day/Night Splits

Using Semax in the morning with a sedating recovery peptide at night (e.g., DSIP) is a practical approach to avoid sleep interference [community protocol].

Semax is approved as a drug in Russia and has been included in the Russian essential medicines list for neurological indications Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. It is not FDA-approved or recognized by other Western regulatory agencies Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

In the United States, Semax is considered an unapproved investigational peptide, and availability typically occurs through grey-market or compounding channels Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

The World Anti-Doping Agency (WADA) prohibits Semax as a peptide with neuroenhancement potential, placing athletes at risk for sanctions "Brain doping" substances: prohibited or not in sports?. No major enforcement actions or athlete sanction cases are documented in the available corpus.

Semax is generally well-tolerated in short-term use, with the most common side effects being mild nasal irritation, transient agitation, or daytime drowsiness Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. Long-term human safety data are limited, as most evidence comes from regional clinical use and animal studies Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Common Side Effects

• Nasal discomfort, sneezing, or throat drip (route-related) Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
• Restlessness, insomnia, or headache, especially with late-day dosing Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives[community protocol]

Theoretical Risks

• Mood destabilization in bipolar spectrum due to BDNF activation Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress
• Altered copper homeostasis from its metal-chelating properties Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity
• Unknown interactions with opioids or serotonergic antidepressants Semax peptide targets the μ opioid receptor gene <i>Oprm1</i> to promote deubiquitination and functional recovery after spinal cord injury in female mice+1

Contraindications

• Recent nasal surgery, active epistaxis, or hypersensitivity to components Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
• Uncontrolled mania, psychosis, or seizure disorders Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
• Pregnancy and breastfeeding due to absent safety data Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives

Routine monitoring of blood pressure, sleep quality, and mood is suggested during cycles [community protocol].